The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria

Zerizer, Imene; Al‐Nahhas, Adil; Towey, David; Tait, Paul; Ariff, Ben; Wasan, Harpreet; Hatice, G; Habib, Nagy; Barwick, Tara

doi:10.1007/s00259-012-2149-1

Cited by 82 publications

(56 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several 18 F-FDG PET studies have reported a prognostic value of metabolic imaging in small patient cohorts, albeit without reporting overall patient survival as an indicator for treatment response (6,7,15). Zerizer et al published an initial report on the correlation between 2-y progression-free survival and 18 F-FDG PET metabolic response as determined by European Organization for Research and Treatment of Cancer (EORTC) criteria in 25 CRC patients (27). In their study, a posttherapeutic change in SUV max of 2.0 or less in the lesion with the highest 18 F-FDG uptake was a strong predictor of progression-free survival, whereas RECIST 1.1 criteria and tumor density criteria, based on those of Choi et al (28), did not emerge as useful prognostic markers.…”

Section: Discussionmentioning

confidence: 99%

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

et al. 2013

View full text Add to dashboard Cite

90 Y radioembolization (selective internal radiation therapy [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary colorectal cancer. The present study evaluated the prognostic value of 18 F-FDG PET/CT metabolic parameters for predicting survival after SIRT. Methods: Eighty patients with hepatic metastases of colorectal cancer were treated with SIRT. 18 F-FDG PET/CT was performed at baseline and 3 mo after the treatment. Metabolic volume, total lesion glycolysis, and maximum and peak standardized uptake value (SUV max and SUV peak , respectively) according to PET Response Criteria in Solid Tumors (PER-CIST 1.0) were obtained from 3 liver lesions in each patient, and the corresponding percentage changes from baseline to follow-up were calculated. Tumor response was defined as more than a 30% decrease in these parameters. Furthermore, response was evaluated in accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Toxicity events and survival were recorded. Results: Overall median survival after SIRT was 60 wk. Responders who had a change in metabolic volume or total lesion glycolysis had significantly longer survival (92 vs. 49 wk [P 5 0.006] and 91 vs. 48 wk [P 5 0.025], respectively). However, neither RECIST 1.1 criteria nor changes in SUV peak or SUV max after treatment predicted outcome (P 5 0.086 for RECIST; P 5 0.310 for change in SUV peak ; P 5 0.155 for change in SUV max ). Conclusion: Changes in metabolic volume and total lesion glycolytic rate as measured by 18 F-FDG PET predicted survival in patients with hepatic metastases from colorectal cancer, whereas changes in SUV peak or SUV max and RECIST 1.1 criteria did not predict survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Assessment of early responses with [ 18 F]FDG PET/CT has been found to be superior to assessment based on the RECIST criteria and changes in tumor density evaluated with CT. Furthermore, PET is the strongest predictor of progression-free survival in patients with liver metastases, demonstrating a correlation with tumor markers [56][57][58].…”

Section: Post-treatment Imaging Workupmentioning

confidence: 99%

Multiagent imaging of liver tumors with reference to intra-arterial radioembolization

Maccauro¹,

Lorenzoni²,

Boni

et al. 2013

Clin Transl Imaging

View full text Add to dashboard Cite

Intra-arterial radioembolization using microspheres labeled with the high-energy beta-emitter yttrium-90 ( 90 Y) is an innovative therapeutic strategy for primary and secondary hepatic malignancies. An accurate imaging workup plays a pivotal role in correctly selecting patients for treatment, to avoid severe complications and in assessment of the post-administration microsphere distribution. Nuclear medicine imaging modalities are an integral part of a complex multidisciplinary approach. In particular, hepatic perfusion imaging with 99m Tc-macroaggregated albumin particles ( 99m Tc-MAA), which identifies extrahepatic accumulation of radiopharmaceutical and lung shunt, is necessary to correctly select patients who may benefit from the treatment. Furthermore, 99m Tc MAA SPECT-based dose planning may optimize RE efficacy, overcoming the limitations of empirical methods to determine the activity to be administered. Quantitative assessment of the post-administration intrahepatic microsphere distribution with SPECT or PET is important for evaluation of toxicity and efficacy and can be used for the prediction of patient response and for patient-specific therapeutic dose optimization. Finally, [ 18 F]FDG PET/CT imaging is important in the assessment of early response after RE and in predicting patient outcome. This review provides a comprehensive overview of multimodality imaging in the complex management of patients undergoing RE for liver tumors.

show abstract

“…The previously cited reports [12,13,18] Y RE by performing FDG PET 6-8 weeks after the procedure [17]. A significant correlation was found between the decrease of SUV max and patients' progression-free survival.…”

mentioning

confidence: 99%

“…Further information on tumour behaviour before and after treatments can be achieved by using total lesion glycolysis (TLG), a PET-derived parameter combining SUV(mean) and MTV [16]. In a large series of 80 patients with colorectal liver metastases, Fendler and coworkers recently tested the validity of these PET-derived parameters for predicting survival of patients with colorectal liver metastases after 90 Y RE [17]. FDG PET was performed at baseline and 3 months after the procedure and TLG, MTV and changes in SUV were calculated.…”

mentioning

confidence: 99%

18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?

Bagni

Filippi

Schillaci

2014

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria

Cited by 82 publications

References 16 publications

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

Multiagent imaging of liver tumors with reference to intra-arterial radioembolization

18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?

Contact Info

Product

Resources

About

The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria

Cited by 82 publications

References 16 publications

Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

Multiagent imaging of liver tumors with reference to intra-arterial radioembolization

18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?

Contact Info

Product

Resources

About

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer

Validation of Several SUV-Based Parameters Derived from ¹⁸F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer